vs
Side-by-side financial comparison of CAMTEK LTD (CAMT) and CORCEPT THERAPEUTICS INC (CORT). Click either name above to swap in a different company.
CAMTEK LTD is the larger business by last-quarter revenue ($242.0M vs $202.1M, roughly 1.2× CORCEPT THERAPEUTICS INC). CAMTEK LTD runs the higher net margin — 28.1% vs 12.0%, a 16.1% gap on every dollar of revenue.
Camtek Ltd is a leading global developer and manufacturer of high-precision inspection and metrology systems for the semiconductor, printed circuit board, and advanced packaging industries. Its solutions support process control, defect detection, and yield optimization for clients across Asia, North America, and Europe.
Corcept Therapeutics Inc. is a pharmaceutical company engaged in the discovery, development and commercialization of drugs for the treatment of severe metabolic, psychiatric and oncologic disorders. Corcept has focused on the adverse effects of excess cortisol, studying new compounds that may mitigate those effects. Its executive team is headed by CEO, president and director Joseph K. Belanoff, MD.
CAMT vs CORT — Head-to-Head
Income Statement — Q2 FY2025 vs Q4 FY2025
| Metric | | |
|---|---|---|
| Revenue | $242.0M | $202.1M |
| Net Profit | $68.0M | $24.3M |
| Gross Margin | 50.9% | 98.7% |
| Operating Margin | 26.7% | 2.2% |
| Net Margin | 28.1% | 12.0% |
| Revenue YoY | — | 11.1% |
| Net Profit YoY | — | -21.0% |
| EPS (diluted) | — | $0.20 |
Green = leading value per metric. Periods may differ when fiscal calendars don't align.
8-Quarter Revenue & Profit Trend
Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.
| Q4 25 | — | $202.1M | ||
| Q3 25 | — | $207.6M | ||
| Q2 25 | $242.0M | $194.4M | ||
| Q1 25 | — | $157.2M | ||
| Q4 24 | — | $181.9M | ||
| Q3 24 | — | $182.5M | ||
| Q2 24 | $199.6M | $163.8M | ||
| Q1 24 | — | $146.8M |
| Q4 25 | — | $24.3M | ||
| Q3 25 | — | $19.7M | ||
| Q2 25 | $68.0M | $35.1M | ||
| Q1 25 | — | $20.5M | ||
| Q4 24 | — | $30.7M | ||
| Q3 24 | — | $47.2M | ||
| Q2 24 | $52.8M | $35.5M | ||
| Q1 24 | — | $27.8M |
| Q4 25 | — | 98.7% | ||
| Q3 25 | — | 97.8% | ||
| Q2 25 | 50.9% | 98.2% | ||
| Q1 25 | — | 98.5% | ||
| Q4 24 | — | 98.4% | ||
| Q3 24 | — | 98.4% | ||
| Q2 24 | 48.1% | 98.5% | ||
| Q1 24 | — | 98.3% |
| Q4 25 | — | 2.2% | ||
| Q3 25 | — | 4.9% | ||
| Q2 25 | 26.7% | 13.7% | ||
| Q1 25 | — | 2.2% | ||
| Q4 24 | — | 13.9% | ||
| Q3 24 | — | 25.5% | ||
| Q2 24 | 23.6% | 21.7% | ||
| Q1 24 | — | 20.1% |
| Q4 25 | — | 12.0% | ||
| Q3 25 | — | 9.5% | ||
| Q2 25 | 28.1% | 18.1% | ||
| Q1 25 | — | 13.1% | ||
| Q4 24 | — | 16.9% | ||
| Q3 24 | — | 25.9% | ||
| Q2 24 | 26.4% | 21.7% | ||
| Q1 24 | — | 18.9% |
| Q4 25 | — | $0.20 | ||
| Q3 25 | — | $0.16 | ||
| Q2 25 | — | $0.29 | ||
| Q1 25 | — | $0.17 | ||
| Q4 24 | — | $0.25 | ||
| Q3 24 | — | $0.41 | ||
| Q2 24 | — | $0.32 | ||
| Q1 24 | — | $0.25 |
Balance Sheet & Financial Strength
Snapshot of each company's liquidity, leverage and book value from the latest quarter.
| Metric | | |
|---|---|---|
| Cash + ST InvestmentsLiquidity on hand | $232.0M | $372.2M |
| Total DebtLower is stronger | — | — |
| Stockholders' EquityBook value | $626.5M | $647.8M |
| Total Assets | $974.7M | $836.7M |
| Debt / EquityLower = less leverage | — | — |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | — | $372.2M | ||
| Q3 25 | — | $421.7M | ||
| Q2 25 | $232.0M | $342.2M | ||
| Q1 25 | — | $322.8M | ||
| Q4 24 | — | $383.3M | ||
| Q3 24 | — | $380.3M | ||
| Q2 24 | $109.8M | $473.2M | ||
| Q1 24 | — | $410.8M |
| Q4 25 | — | $647.8M | ||
| Q3 25 | — | $631.9M | ||
| Q2 25 | $626.5M | $635.8M | ||
| Q1 25 | — | $683.3M | ||
| Q4 24 | — | $679.6M | ||
| Q3 24 | — | $638.8M | ||
| Q2 24 | $475.4M | $596.2M | ||
| Q1 24 | — | $547.9M |
| Q4 25 | — | $836.7M | ||
| Q3 25 | — | $823.6M | ||
| Q2 25 | $974.7M | $801.7M | ||
| Q1 25 | — | $846.5M | ||
| Q4 24 | — | $840.6M | ||
| Q3 24 | — | $784.3M | ||
| Q2 24 | $796.2M | $714.6M | ||
| Q1 24 | — | $655.9M |
Cash Flow & Capital Efficiency
How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.
| Metric | | |
|---|---|---|
| Operating Cash FlowLast quarter | $47.1M | $38.4M |
| Free Cash FlowOCF − Capex | — | $38.4M |
| FCF MarginFCF / Revenue | — | 19.0% |
| Capex IntensityCapex / Revenue | — | 0.0% |
| Cash ConversionOCF / Net Profit | 0.69× | 1.58× |
| TTM Free Cash FlowTrailing 4 quarters | — | — |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | — | $38.4M | ||
| Q3 25 | — | $54.5M | ||
| Q2 25 | $47.1M | $43.9M | ||
| Q1 25 | — | $5.1M | ||
| Q4 24 | — | $59.3M | ||
| Q3 24 | — | $73.8M | ||
| Q2 24 | $70.1M | $41.2M | ||
| Q1 24 | — | $23.8M |
| Q4 25 | — | $38.4M | ||
| Q3 25 | — | — | ||
| Q2 25 | — | $43.9M | ||
| Q1 25 | — | $5.0M | ||
| Q4 24 | — | $59.2M | ||
| Q3 24 | — | $72.2M | ||
| Q2 24 | — | $40.8M | ||
| Q1 24 | — | — |
| Q4 25 | — | 19.0% | ||
| Q3 25 | — | — | ||
| Q2 25 | — | 22.6% | ||
| Q1 25 | — | 3.2% | ||
| Q4 24 | — | 32.5% | ||
| Q3 24 | — | 39.5% | ||
| Q2 24 | — | 24.9% | ||
| Q1 24 | — | — |
| Q4 25 | — | 0.0% | ||
| Q3 25 | — | 0.0% | ||
| Q2 25 | — | 0.0% | ||
| Q1 25 | — | 0.1% | ||
| Q4 24 | — | 0.1% | ||
| Q3 24 | — | 0.9% | ||
| Q2 24 | — | 0.3% | ||
| Q1 24 | — | 0.0% |
| Q4 25 | — | 1.58× | ||
| Q3 25 | — | 2.77× | ||
| Q2 25 | 0.69× | 1.25× | ||
| Q1 25 | — | 0.25× | ||
| Q4 24 | — | 1.93× | ||
| Q3 24 | — | 1.56× | ||
| Q2 24 | 1.33× | 1.16× | ||
| Q1 24 | — | 0.86× |
Financial Flow Comparison
Revenue → gross profit → operating profit → net profit for each company.
